An α-tocopheryl succinate enzyme-based nanoassembly for cancer imaging and therapy
Nanoassembly (NA) based on a D-α-tocopherol succinate (αTS) conjugated lysozyme (Lys) (Lys-αTS) was fabricated for tumor-selective delivery of curcumin (CUR) for breast cancer therapy. Lys and αTS were used as a biocompatible enzyme and a hydrophobic residue, respectively, for the preparation of nan...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-01-01
|
| Series: | Drug Delivery |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/10717544.2018.1446476 |
| _version_ | 1818313941998108672 |
|---|---|
| author | Song Yi Lee Hyun-Jong Cho |
| author_facet | Song Yi Lee Hyun-Jong Cho |
| author_sort | Song Yi Lee |
| collection | DOAJ |
| description | Nanoassembly (NA) based on a D-α-tocopherol succinate (αTS) conjugated lysozyme (Lys) (Lys-αTS) was fabricated for tumor-selective delivery of curcumin (CUR) for breast cancer therapy. Lys and αTS were used as a biocompatible enzyme and a hydrophobic residue, respectively, for the preparation of nanocarriers in this study. Compared with CUR-loaded cross-linked Lys (c-Lys/CUR) NA, Lys-αTS/CUR NA exhibited a smaller hydrodynamic size (213 nm mean diameter), a narrower size distribution, and a more spherical shape. Sustained drug release was observed from the Lys-αTS/CUR NA for five days at a normal physiological pH (pH 7.4). The developed Lys-αTS/CUR NA showed enhanced cellular accumulation, antiproliferative effects, and apoptotic efficacies in MDA-MB-231 human breast adenocarcinoma cells. According to the results of optical imaging test in the MDA-MB-231 tumor-bearing mouse models, the Lys-αTS/CUR NA-injected group exhibited a more tumor-selective accumulation pattern, rather than being distributed in the normal tissues and organs. The observed tumor targetability of Lys-αTS/CUR was further studied, which revealed improved in vivo anticancer activities (better inhibition of tumor growth and induction of apoptosis in the tumor tissue) after an intravenous administration in the MDA-MB-231 tumor-bearing mouse models. All these results indicate that the newly developed enzyme-based nanocarrier, the Lys-αTS NA, can be a promising candidate for the therapy of breast cancers. |
| first_indexed | 2024-12-13T08:41:45Z |
| format | Article |
| id | doaj.art-362b7d95ff37467a9a63886faafa0817 |
| institution | Directory Open Access Journal |
| issn | 1071-7544 1521-0464 |
| language | English |
| last_indexed | 2024-12-13T08:41:45Z |
| publishDate | 2018-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Drug Delivery |
| spelling | doaj.art-362b7d95ff37467a9a63886faafa08172022-12-21T23:53:31ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642018-01-0125173874910.1080/10717544.2018.14464761446476An α-tocopheryl succinate enzyme-based nanoassembly for cancer imaging and therapySong Yi Lee0Hyun-Jong Cho1Kangwon National UniversityKangwon National UniversityNanoassembly (NA) based on a D-α-tocopherol succinate (αTS) conjugated lysozyme (Lys) (Lys-αTS) was fabricated for tumor-selective delivery of curcumin (CUR) for breast cancer therapy. Lys and αTS were used as a biocompatible enzyme and a hydrophobic residue, respectively, for the preparation of nanocarriers in this study. Compared with CUR-loaded cross-linked Lys (c-Lys/CUR) NA, Lys-αTS/CUR NA exhibited a smaller hydrodynamic size (213 nm mean diameter), a narrower size distribution, and a more spherical shape. Sustained drug release was observed from the Lys-αTS/CUR NA for five days at a normal physiological pH (pH 7.4). The developed Lys-αTS/CUR NA showed enhanced cellular accumulation, antiproliferative effects, and apoptotic efficacies in MDA-MB-231 human breast adenocarcinoma cells. According to the results of optical imaging test in the MDA-MB-231 tumor-bearing mouse models, the Lys-αTS/CUR NA-injected group exhibited a more tumor-selective accumulation pattern, rather than being distributed in the normal tissues and organs. The observed tumor targetability of Lys-αTS/CUR was further studied, which revealed improved in vivo anticancer activities (better inhibition of tumor growth and induction of apoptosis in the tumor tissue) after an intravenous administration in the MDA-MB-231 tumor-bearing mouse models. All these results indicate that the newly developed enzyme-based nanocarrier, the Lys-αTS NA, can be a promising candidate for the therapy of breast cancers.http://dx.doi.org/10.1080/10717544.2018.1446476α-tocopherol succinatecurcuminlysozymenanoassemblytumor targeting |
| spellingShingle | Song Yi Lee Hyun-Jong Cho An α-tocopheryl succinate enzyme-based nanoassembly for cancer imaging and therapy Drug Delivery α-tocopherol succinate curcumin lysozyme nanoassembly tumor targeting |
| title | An α-tocopheryl succinate enzyme-based nanoassembly for cancer imaging and therapy |
| title_full | An α-tocopheryl succinate enzyme-based nanoassembly for cancer imaging and therapy |
| title_fullStr | An α-tocopheryl succinate enzyme-based nanoassembly for cancer imaging and therapy |
| title_full_unstemmed | An α-tocopheryl succinate enzyme-based nanoassembly for cancer imaging and therapy |
| title_short | An α-tocopheryl succinate enzyme-based nanoassembly for cancer imaging and therapy |
| title_sort | α tocopheryl succinate enzyme based nanoassembly for cancer imaging and therapy |
| topic | α-tocopherol succinate curcumin lysozyme nanoassembly tumor targeting |
| url | http://dx.doi.org/10.1080/10717544.2018.1446476 |
| work_keys_str_mv | AT songyilee anatocopherylsuccinateenzymebasednanoassemblyforcancerimagingandtherapy AT hyunjongcho anatocopherylsuccinateenzymebasednanoassemblyforcancerimagingandtherapy AT songyilee atocopherylsuccinateenzymebasednanoassemblyforcancerimagingandtherapy AT hyunjongcho atocopherylsuccinateenzymebasednanoassemblyforcancerimagingandtherapy |